BioSpace News Archive

Bicycle Therapeutics plc today announced an update regarding shareholder attendance at its 2021 Annual General Meeting (the “AGM”) to be held on June 28, 2021.

AVITA Medical, Inc. today announced preliminary, unaudited financial results for the fiscal fourth quarter 2021.

Growing need to monitor chronic inflammatory conditions, increasing CVD in geriatric population, and rising use of C-reactive protein in clinical diagnostics are key factors driving market growth.

Rising prevalence of disruptive behavior disorders globally and increasing demand for treatment of same are expected to fuel market growth.

Inhibikase Therapeutics, Inc. today announced the pricing of an underwritten public offering of 15 million shares of its common stock.

Government initiatives and investments by key players to develop advanced tests and kits for detecting Zika virus are key factors fueling global market growth.

RAPT Therapeutics, Inc. announced the pricing of its previously announced underwritten public offering of 3,787,879 shares of its common stock at a price to the public of $33.00 per share.

SGD Pharma announces that its 20ml EasyLyo molded glass Type I vials are now available Ready-to-Use (RTU) in SG EZ-fill® Nest & Tub – an industry-recognized state-of-the-art secondary packaging format.

SQI Diagnostics Inc. (“SQI” or the “Company”) (TSXV: SQD) (OTCQB: SQIDF), a life sciences and diagnostics company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics today announces that certain insiders of the Company, who are control persons (the “Control Persons”),

Editas Medicine, Inc. today announced the grant of inducement awards to the Company’s newly appointed Executive Vice President and Chief Scientific Officer, Mark Shearman, Ph.D., and Senior Vice President and Chief Regulatory Officer, Chi Li, Ph.D.